Novel antiproliferative antitumor agents

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 5, 2005, Pages 613-618

  Mader, Mary M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cancer; CHS 828; Cytotoxic; EB 1627; LY 573636; SPC 595

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 5 AMINO 6,8 DIFLUORO 2 (3 FLUOROPHENYL) 7 METHYL 4H 1 BENZOPYRAN 4 ONE; 5 CHLOROSULFAQUINOXALINE; A 65282; ACYLSULFONAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIPROLIFERATIVE AGENT; COLCHICINE; CP 115953; DOXORUBICIN; EB 1627; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; LY 573636; MX 116407; MX 58151; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; NOSCAPINE; NOSCAPINE DERIVATIVE; PRODRUG; QUINOLINE DERIVATIVE; SPARFOSIC ACID; SPC 595; TETRAPLATIN; UNCLASSIFIED DRUG; VINBLASTINE; WIN 57294;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HUMAN; REVIEW; SCREENING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 24044549325     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Paz-Ares L, Bezares S, Tabemero JM, Castellanos D, Cortes-Funes H: Review of a promising new agent - pemetrexed disodium. Cancer (2003) 97(8 Suppl):2056-2063.
2. Issa J-P, Kantarjian H, Kirkpatrick P: Azacitidine. Nat Rev Drug Discov (2005) 4(4):275-276.
3. Perez-Soler R: The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res (2004) 10(12 Pt 2):4238s-4240s.
4. Stemberg A: Clofarabine. Curr Opin Invest Drugs (2003) 4(12):1479-1487.
5. Laird AD, Cherrington JM: Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin Invest Drugs (2003) 12(1):51-64.
6. Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer (2005) 5(1):65-72. Provides a review of the strategies employed in the discovery and development of cancer chemotherapies from the 1940s to the present day.
7. Clinical Trials. gov: National Institutes of Health, Bethesda, MD, USA (2005). http://www.clinicaltrials.gov
8. Lobb KL, Hipskind PA, Aikins JA, Alvarez E, Cheung YY, Considine EL, De Dios A, Durst GL, Ferritto R, Grossman CS, Giera DD et al: Acyl sulfonamide antiproliferatives: Benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem (2004) 47(22):5367-5380. Describes the discovery, synthesis and SAR of the first acylsulfonamide antiproliferative series from Eli Lilly.
9. Mader MM, Shih C, Considine E, Dios AD, Grossman CS, Hipskind PA, Lin HS, Lobb KL, Lopez B, Lopez JE, Cabrejas LM et al: Acyl sulfonamide antiproliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives. Bioorg Med Chem Lett (2005) 15(3):617-620.
10. Lipinski CA, Lombarde F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 46(1-3):3-26.
11. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fomace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK et al: An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 275(5298):343-349.
12. Simon G, Sovak M, Wagner M, Haura E, Gerst S, deAlwis D, Bepler G, Sullivan D, Weitzman A, Spriggs D: A phase I trial of LY573636 in patients with advanced solid tumors. Eur J Cancer Suppl (2004) 2(8):Abs 228.
13. Tomita K, Tsuzuki Y, Shibamori K, Tashima M, Kajikawa F, Sato Y, Kashimoto S, Chiba K, Hino K: Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acids as antitumor agents. Part 1. J Med Chem (2002) 45(25):5564-5575. Describes the discovery, synthesis and SAR of the SPC-595 family of compounds.
14. Kohlbrenner WE, Wideburg N, Weigl D, Saldivar A, Chu DT: Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282. Antimicrob Agents Chemother (1992) 36(1):81-86.
15. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N: Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrob Agents Chemother (1992) 36(4):751-756.
16. Wentland MP, Lesher GY, Reuman M, Gruett MD, Singh B, Aldous SC, Dorff PH, Rake JB, Coughlin SA: Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl) -4-oxo-3-quinolinecarboxylic acid and related derivatives. J Med Chem (1993) 36(19):2801-2809.
17. Hoch U, Hyde J, Nannini MA, Evanchik MJ, Lawrence CE, Arkin MR, Walker DH, Silverman JA: SNS-595, a novel cell cycle inhibitor in phase I clinical trials, causes tumor regressions, cell-cycle arrest and apoptosis in murine models of colon cancer. Proc Am Assoc Cancer Res (2005) 46:Abs 2277.
18. 2 arrest. Proc Am Assoc Cancer Res (2005) 46:Abs 2293.
19. Schou C, Ottosen ER, Petersen HJ, Bjorkling F, Latini S, Hjamaa PV, Bramm E, Binderup L: Novel cyanoguanidines with potent oral antitumor activity. Bioorg Med Chem Lett (1997) 7(24):3095-3100. The initial report of the antitumor activity of the cyanoguanidine derivatives.
20. Hjamaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, Skov T, Binderup L: CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res (1999) 59(22):5751-5757.
21. Olsen LS, Hjamaa PJ, Latini S, Holm PK, Larsson R, Bramm E, Binderup L, Madsen MW: Anticancer agent CHS 828 suppresses nuclear factor-κB activity in cancer cells through downregulation of IKK activity. Int J Cancer (2004) 111(2):198-205.
22. Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer AM, Krasilnikoff K, Bergh J, Kartsson MO, Loennebo A, Ahlgren J: A phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res (2002) 8(9):2843-2850.
23. Lindhagen E, Vig Hjarnaa P-J, Friberg LE, Latini S, Larsson R: Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828. Drug Dev Res (2004) 61(4):218-226.
24. Binderup E, Björkling F, Hjarnaa PV, Latini S, Baltzer B, Carlsen M, Binderup L: EB1627: A soluble prodrug of the potent anticancer cyanoguanidine CHS828. Bioorg Med Chem Lett (2005) 15(10):2491-2494.
25. Kemnitzer W, Drewe J, Jiang S, Zhang H, Wang Y, Zhao J, Jia S, Herich J, Labreque D, Storer R, Meerovitch K et al: Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group. J Med Chem (2004) 47(25):6299-6310.
26. Kasibhatla S, Gourdeau H, Meerovitch K, Drewe J, Reddy S, Qiu L, Zhang H, Bergeron F, Bouffard D, Yang Q, Herich J et al: Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol Cancer Ther (2004) 3(11):1365-1374.
27. Gourdeau H, Leblond L, Hamelin B, Desputeau C, Dong K, Kianicka I, Custeau D, Boudreau C, Geerts L, Cai SX, Drewe J et al: Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4H- chromenes, a novel series of anticancer agents. Mol Cancer Ther (2004) 3(11):1375-1384.
28. Akama T, Shida Y, Sugaya T, Ishida H, Gomi K, Kasai M: Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem (1996) 39(18):3461-3469.
29. Akama T, Ishida H, Shida Y, Kimura U, Gomi K, Saito H, Fuse E, Kobayashi S, Yoda N, Kasai M: Design and synthesis of potent antitumor 5,4′-diaminoflavone derivatives based on metabolic considerations. J Med Chem (1997) 40(12):1894-1900.
30. Akama T, Ishida H, Kimura U, Gomi K, Saito H: Structure-activity relationships of the 7-substituents of 5,4′-diamino-6,8,3′- trifluoroflavone, a potent antitumor agent. J Med Chem (1998) 41(12):2056-2067.
31. Kuffel MJ, Schroeder JC, Pobst U, Naylor S, Reid JM, Kaufmann SH, Ames MM: Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol (2002) 62(1):143-153.
32. Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA: Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther (2004) 3(6):715-725.
33. Ferlin MG, Chiarelotto G, Gasparotto V, Dalla Via L, Pezzi V, Barzon L, Palu G, Castagliuolo I: Synthesis and in vitro and in vivo antitumor activity of 2-phenylpyrroloquinolin-4-ones. J Med Chem (2005) 48(9):3417-3427.
34. Nemoto T, Ohshima T, Shibasaki M: Enantioselective total syntheses of (+)-decursin and related natural compounds using catalytic asymmetric epoxidation of an enone. Tetrahedron (2003) 59(35):6889-6897.
35. Lee S, Lee YS, Jung SH, Shin KH, Kim BK, Kang SS: Antitumor activities of decursinol angelate and decursin from Angelica gigas. Arch Pharm Res (2003) 26(9):727-730.
36. 1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res (2005) 65(3):1035-1044.
37. Anderson JT, Ting AE, Boozer S, Brunden KR, Danzig J, Dent T, Harrington JJ, Murphy SM, Perry R, Raber A, Rundlett SE et al: Discovery of S-phase arresting agents derived from noscapine. J Med Chem (2005) 48(8):2756-2758.
38. Kamb A: What's wrong with our cancer models? Nat Rev Drug Discov (2005) 4(2):161-164. Reviews the challenges in correlating oncolytic activity in rodent models with clinical experience and discusses the progress made in addressing the challenges.